Researchers have developed the world’s first human vaccines designed entirely by artificial intelligence (AI), with significant breakthroughs reported between 2019 and 2026. This innovation began when Flinders University in South Australia used its AI program, SAM (Search Algorithm for Ligands), in July 2019 to create a flu vaccine candidate specifically engineered to activate the human immune system. AI-driven vaccine research has since expanded to target severe diseases, improve strain selection, and accelerate pandemic preparedness through international collaborations and new design platforms.
How AI Is Transforming Vaccine Design Globally
SAM, the AI tool at Flinders University, was trained on a database of compounds to distinguish those capable of stimulating the human immune system. Professor Nikolai Petrovsky, a lead researcher on the project, explained, “We had to teach the AI program on a set of compounds that are known to activate the human immune system, and a set of compounds that don’t work.” The resulting vaccine underwent 12-month clinical trials funded by the US National Institute of Allergy and Infectious Diseases, marking a pivotal moment in AI-directed biomedical discovery, according to Flinders University.
Building on this foundation, Baidu Research in China reported in May 2023 that its proprietary AI algorithm could significantly improve the stability and antibody response of mRNA COVID-19 vaccines. He Zhang of Baidu noted, “Enumerating all COVID-19 mRNA vaccine sequences would take 10616 billion years, but our algorithm designs the most stable mRNA in just 11 minutes.” The practicality of rapid design has implications for future pandemic response and control.
Internationally, research institutes and companies have accelerated work on AI-based vaccine design. In August 2025, the Massachusetts Institute of Technology (MIT) introduced ‘VaxSeer,’ an AI system aimed at enhancing flu vaccine strain selection. The Oxford–Ellison Institute’s £118 million CoI-AI research programme, launched in September 2025, is focused on applying AI to understand immunity correlates and drive next-generation immunisation strategies.
Implications For Global Health And Future Vaccines
In December 2025, the Houston Methodist Research Institute, with CEPI and South Korean partners, developed the first AI-based mRNA vaccine targeting severe fever with thrombocytopenia syndrome (SFTS), a tick-borne viral infection, signalling how AI is extending into emerging infectious disease control. Dr. Jimmy Gollihar of Houston Methodist stated, “By working hand-in-hand with our partners in Korea and CEPI on this SFTS ‘prototype’ vaccine, we aim to design components that are both safer and capable of eliciting broad, durable protection.”
In March 2026, Danish biotech Evaxion and the Gates Foundation announced AI-powered polio vaccine design concepts through the AI-Immunology™ platform, aiming to address diseases still burdening lower- and middle-income countries. These advancements signal a reimagining of conventional vaccine timelines and may improve access to life-saving drugs worldwide—including in countries such as South Africa where infectious disease control remains a priority.
Experts and public health institutions say integrating AI into vaccine development could allow for faster, more targeted responses to outbreaks, reduced manufacturing costs, and precise tailoring of vaccines to different populations. Collaborative international efforts demonstrate the growing importance of AI for global health security, especially as new diseases and mutations challenge traditional medical research methods.
Further clinical trials and regulatory reviews of AI-designed vaccines are expected in coming years, with potential impact for South African biotechnology engagement and public health policy.